ArticleThe American journal of drug and alcohol abuse2010
Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS).
Article in The American journal of drug and alcohol abuse, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Care for patients with cancer and substance use disorders: a qualitative study of oncology team experiences.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Article
- The impact of substance use on health care utilization, treatment, and outcomes in patients with non-small cell lung cancer.Journal of thoracic disease · 2022Article
- An Interdisciplinary Approach to Metastatic Pancreatic Cancer and Comorbid Opioid Use Disorder Treatment Within a VA Health Care System.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2021Article
- Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies.Molecules (Basel, Switzerland) · 2021Review
- Co-occurring substance use disorder: The impact on treatment adherence in women with locally advanced cervical cancer.Gynecologic oncology reports · 2019Article
- Association between age, substance use, and outcomes in Medicare enrollees with prostate cancer.Journal of geriatric oncology · 2016Article
- Identifying and assessing the risk of opioid abuse in patients with cancer: an integrative review.Substance abuse and rehabilitation · 2016Review
- Substance use disorder and its effects on outcomes in men with advanced-stage prostate cancer.Cancer · 2014Article
- Predictors of neuropsychological change in patients with chronic myelogenous leukemia and myelodysplastic syndrome.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPatients' substance use problems are a particularly understudied aspect of psychosocial variables in cancer treatment.
objectivesThe specific hypothesis tested was that lifetime substance use disorders increased the risk of adverse outcome, in the context of other psychosocial and clinical characteristics demonstrated in other studies to have an impact on treatment outcome.
methodProspective cohort study of 106 adults with chronic myelogenous leukemia or primary myelodysplastic syndrome. None satisfied criteria for current substance abuse or dependence, but the lifetime rates of substance use disorders in this sample were 28% for alcohol, 12% for cannabis, and 9% for cocaine.
resultsParticipants received treatment as directed by their physicians, and were followed until death or the end of the study (median 1.5 years). Twenty-eight died. Multivariate survival analysis identified three predictors of outcome: lifetime cocaine use, associated with a six-fold increased risk of death (p = .04), and two protective variables, baseline hemoglobin (p = .002) and estimated intelligence quotient (IQ) (p = .04).
conclusionThe results of this study highlight the potential significance of substance use disorders, and lifetime cocaine diagnoses in particular, on treatment outcome for people with chronic myelogenous leukemia or myelodysplastic syndrome. Whereas neither lifetime alcohol nor cannabis use were associated with survival on either the univariate or multivariate models of survival, lifetime cocaine diagnoses were associated with significant six-fold increased risk of death (p = .04).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.